secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2023-10-16T23:59:59+00:00
Accession:  0001013762-23-003933
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MoonLake announces positive 24-week Phase 2 MIRA results; 57% HiSCR75, 120mg dose confirmed for Phase 3
--------------------------------------------------------------------------------

- 57% of patients on sonelokimab 120mg achieved HiSCR75 at week 24 (+10 ppt from week 12); 38% achieved HiSCR90 (+14 ppt).
- Complete inflammatory remission (IHS4-100) in 24% of patients; 31% AN 100 and 49% DT 100 at week 24 with 120mg.
- 120mg Q4W maintenance dose confirmed as optimal based on efficacy, safety, and pharmacokinetics; safety consistent with IL-17 class.
- Adalimumab non-responders switching to sonelokimab at week 12 achieved HiSCR75 rates similar to patients randomized to sonelokimab at baseline.
- Company on track to discuss Phase 3 development plans with FDA by end of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000101376223003933/0001013762-23-003933-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000101376223003933/ea186779-8k_moonlake.htm
  HTML page:      https://secwatch.observer/filing/0001013762-23-003933

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer